Kapara A, Vannini A, Peck B(2020). A micronutrient with major effects on cancer cell viability. Nature Metabolism
Peck B, Schulze A(2019). Lipid Metabolism at the Nexus of Diet and Tumor Microenvironment. Trends in Cancer vol. 5, (11) 693-703.
Jones DT, Valli A, Haider S, Zhang Q, Smethurst EA, Schug ZT, Peck B, Aboagye EO et al.(2018). 3D Growth of Cancer Cells Elicits Sensitivity to Kinase Inhibitors but Not Lipid Metabolism Modifiers. Molecular Cancer Therapeutics vol. 18, (2) 376-388.
Miess H, Dankworth B, Gouw AM, Rosenfeldt M, Schmitz W, Jiang M, Saunders B, Howell M et al.(2018). The glutathione redox system is essential to prevent ferroptosis caused by impaired lipid metabolism in clear cell renal cell carcinoma. Oncogene vol. 37, (40) 5435-5450.
Leonidou A, Peck B, Natrajan R(2017). Identification and Validation of Driver Kinases from Next-Generation Sequencing Data. Methods Mol Biol vol. 1636, 179-195.
Morrison E, Wai P, Leonidou A, Bland P, Khalique S, Farnie G, Daley F, Peck B et al.(2016). Utilizing Functional Genomics Screening to Identify Potentially Novel Drug Targets in Cancer Cell Spheroid Cultures. J Vis Exp (118)
Maguire SL, Peck B, Wai PT, Campbell J, Barker H, Gulati A, Daley F, Vyse S et al.(2016). Three-dimensional modelling identifies novel genetic dependencies associated with breast cancer progression in the isogenic MCF10 model. J Pathol vol. 240, (3) 315-328.
Peck B, Schulze A(2016). Lipid desaturation - the next step in targeting lipogenesis in cancer?. FEBS J vol. 283, (15) 2767-2778.
Peck B, Schug ZT, Zhang Q, Dankworth B, Jones DT, Smethurst E, Patel R, Mason S et al.(2016). Inhibition of fatty acid desaturation is detrimental to cancer cell survival in metabolically compromised environments. Cancer Metab vol. 4,
Lewis CA, Brault C, Peck B, Bensaad K, Griffiths B, Mitter R, Chakravarty P, East P et al.(2015). SREBP maintains lipid biosynthesis and viability of cancer cells under lipid- and oxygen-deprived conditions and defines a gene signature associated with poor survival in glioblastoma multiforme. Oncogene vol. 34, (40) 5128-5140.
Schug ZT, Peck B, Jones DT, Zhang Q, Grosskurth S, Alam IS, Goodwin LM, Smethurst E et al.(2015). Acetyl-CoA synthetase 2 promotes acetate utilization and maintains cancer cell growth under metabolic stress. Cancer Cell vol. 27, (1) 57-71.
Bensaad K, Favaro E, Lewis CA, Peck B, Lord S, Collins JM, Pinnick KE, Wigfield S et al.(2014). Fatty acid uptake and lipid storage induced by HIF-1α contribute to cell growth and survival after hypoxia-reoxygenation. Cell Rep vol. 9, (1) 349-365.
Peck B, Schulze A(2014). Cholesteryl esters: fueling the fury of prostate cancer. Cell Metab vol. 19, (3) 350-352.
Schug Z, Peck B, Jones D, Zhang Q, Alam I, Witney T, Smethurst E, Grosskurth S et al.(2014). Acetyl-coA synthetase 2 promotes acetate utilization and maintains cell growth under metabolic stress. Cancer & metabolism vol. 2, (Suppl 1) O9-O9.
Baenke F, Peck B, Miess H, Schulze A(2013). Hooked on fat: the role of lipid synthesis in cancer metabolism and tumour development. Dis Model Mech vol. 6, (6) 1353-1363.
Griffiths B, Lewis CA, Bensaad K, Ros S, Zhang Q, Ferber EC, Konisti S, Peck B et al.(2013). Sterol regulatory element binding protein-dependent regulation of lipid synthesis supports cell survival and tumor growth. Cancer Metab vol. 1, (1)
Peck B, Ferber EC, Schulze A(2013). Antagonism between FOXO and MYC Regulates Cellular Powerhouse. Front Oncol vol. 3,
Ferber EC, Peck B, Delpuech O, Bell GP, East P, Schulze A(2012). FOXO3a regulates reactive oxygen metabolism by inhibiting mitochondrial gene expression. Cell Death Differ vol. 19, (6) 968-979.
Peck B, Schulze A(2011). A role for the cancer-associated miR-106b~25 cluster in neuronal stem cells. Aging (Albany NY) vol. 3, (4) 329-331.
Peck B, Chen CY, Ho KK, Di Fruscia P, Myatt SS, Charles Coombes R, Fuchter MJ, Hsiao CD et al.(2010). SIRT inhibitors induce cell death and p53 acetylation through targeting both SIRT1 and SIRT2. Molecular Cancer Therapeutics vol. 9, (4) 844-855.
Kwok JM-M, Peck B, Monteiro LJ, Schwenen HDC, Millour J, Coombes RC, Myatt SS, Lam EW-F(2010). FOXM1 confers acquired cisplatin resistance in breast cancer cells. Mol Cancer Res vol. 8, (1) 24-34.
Francis RE, Myatt SS, Krol J, Hartman J, Peck B, McGovern UB, Wang J, Guest SK et al.(2009). FoxM1 is a downstream target and marker of HER2 overexpression in breast cancer. Int J Oncol vol. 35, (1) 57-68.
McGovern UB, Francis RE, Peck B, Guest SK, Wang J, Myatt SS, Krol J, Kwok JM-M et al.(2009). Gefitinib (Iressa) represses FOXM1 expression via FOXO3a in breast cancer. Mol Cancer Ther vol. 8, (3) 582-591.